Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7000
+0.0217 (3.20%)
At close: Jun 6, 2025, 4:00 PM
0.6999
-0.0001 (-0.01%)
After-hours: Jun 6, 2025, 7:31 PM EDT
Xilio Therapeutics Revenue
Xilio Therapeutics had revenue of $2.93M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $9.27M. In the year 2024, Xilio Therapeutics had annual revenue of $6.34M.
Revenue (ttm)
$9.27M
Revenue Growth
n/a
P/S Ratio
4.92
Revenue / Employee
$144,906
Employees
64
Market Cap
36.25M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
XLO News
- 1 day ago - Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewsWire
- 3 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering - GlobeNewsWire
- 5 days ago - Xilio Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 7 days ago - Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - GlobeNewsWire